Growth of Uveal Melanoma following Intravitreal Bevacizumab | Zendy

Jasmine H. Francis | Zendy; Jonathan Kim | Zendy; Amy Lin | Zendy; Robert Folberg | Zendy; Saipriya Iyer | Zendy; David H. Abramson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Growth of Uveal Melanoma following Intravitreal Bevacizumab

Author(s) -

Jasmine H. Francis,

Jonathan Kim,

Amy Lin,

Robert Folberg,

Saipriya Iyer,

David H. Abramson

Publication year - 2016

Publication title -

ocular oncology and pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.444

H-Index - 10

eISSN - 2296-4681

pISSN - 2296-4657

DOI - 10.1159/000450859

Subject(s) - bevacizumab , medicine , enucleation , vasculogenic mimicry , melanoma , ophthalmology , brachytherapy , metastasis , ocular melanoma , chemotherapy , surgery , cancer , cancer research , radiation therapy

Typically treatment of large melanomas (by Collaborative Ocular Melanoma Study criteria) is restricted to enucleation, due to size constraints for plaque brachytherapy. Because primary and metastatic uveal melanoma cells are inhibited by bevacizumab (an anti-vascular endothelial growth factor), this prospective study evaluated the impact of intravitreal bevacizumab on large uveal melanomas that were destined for enucleation. Size reduction by bevacizumab would potentially salvage these eyes by making them eligible for treatment with plaque brachytherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research